Executive Summary
The global Active Pharmaceutical Ingredients (API) Market was valued at USD 179.6 Billion in the year 2020. Growth opportunities for the Active Pharmaceutical Ingredient market is attributed to the growth of the geriatric population, rising technical advancements, increasing API manufacturing facilities in the world and increasing number of research and development activities by some of the key market players in the global platform.
Additionally, growing awareness, as well as investments in the development of new drugs in the market, is pushing the number of clinical trials in the world which is driving the Active Pharmaceutical Ingredient market. With the rising prevalence of respiratory diseases due to the outbreak of COVID-19, it is expected that there will be more demand for new drugs which is likely to push the demand for API and consequently affect the Global Active Pharmaceutical Market in the world.
The biopharma companies are opting for mergers and acquisitions to gain access to new technologies, expand their market area and increase their capital for clinical trials and investments. The API market has been witnessing impressive growth over the past few years. This growth trend is projected to continue due to the increase in demand from the Asia Pacific region in the future. This is mainly driven by China, India and Japan which consist of a huge population and thereby huge incidence of infectious diseases which require medicines for treatment.
Furthermore, the rising death toll and spread of the virus prompted many pharmaceutical companies, biopharmaceutical companies and small start-ups to collaborate and bring out effective medicine to fight the same. Scientists all over the world found molecules that can effectively target COVID-19. Currently, 155 molecules are under clinical investigation, and 45 molecules are under preclinical development to be targeted against COVID-19. Companies monitored locally to protect the safety of study participants, staff and employees during such times.
Scope of the Report
• The report analyses the Active Pharmaceutical Ingredients Market by Value (USD Billion)
• The report analyses the Active Pharmaceutical Ingredients Market by Application (Oncology, Cardiology, Diabetes, Neurology, Others).
• The report analyses the Active Pharmaceutical Ingredients Market by Drug Type (Generic API, Innovative API)
• The report analyses the Active Pharmaceutical Ingredients Market by Synthesis (Synthetic, Biotech)
• The Global Active Pharmaceutical Ingredients Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA).
• The Global Active Pharmaceutical Ingredients Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India).
• The attractiveness of the market has been presented by region, by Application, by Drug Type and by Synthesis.
• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
• The companies analysed in the report include Pfizer Inc., GlaxoSmithKline, AbbVie Inc., Novartis AG, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sanofi, Bristol-Myers Squibb and Boehringer Ingelheim.
• The report presents the analysis of the Active Pharmaceutical Ingredients market for the historical period of 2016-2020 and the forecast period of 2021-2026.
Key Target Audience
• Active Pharmaceutical Ingredients Manufacturers
• Pharmaceutical Companies
• Consulting and Advisory Firms
• Government and Policy Makers
• Regulatory Authorities
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Global Active Pharmaceutical Ingredient Market: Product Outlook
4. Global Active Pharmaceutical Ingredient Market: Size and Forecast
4.1 Global Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026
5. Global Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis
5.1 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Application
5.1.1 Oncology - Market Size and Forecast (2016-2026)
5.1.2 Cardiology- Market Size and Forecast (2016-2026)
5.1.3 Diabetes - Market Size and Forecast (2016-2026)
5.1.4 Neurology - Market Size and Forecast (2016-2026)
5.1.5 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Drug Type
5.2.1 Generic API- Market Size and Forecast (2016-2026)
5.2.2 Innovative API - Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Synthesis
5.3.1 Synthetic - Market Size and Forecast (2016-2026)
5.3.2 Biotech - Market Size and Forecast (2016-2026)
6. Global Active Pharmaceutical Ingredient Market: Regional Analysis
6.1 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Region
7. North America Active Pharmaceutical Ingredient Market: An Analysis (2016-2026)
7.1 North America Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026)
7.2 North America Active Pharmaceutical Ingredient Market - Prominent Companies
7.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others)
7.4 Market Segmentation By Drug Type (Generic API and Innovative API)
7.5 Market Segmentation By Synthesis (Synthetic and Biotech)
7.6 North America Active Pharmaceutical Ingredient Market: Country Analysis
7.7 Market Opportunity Chart of North America Active Pharmaceutical Ingredient Market - By Country, By Value, 2026
7.8 Competitive Scenario of North America Active Pharmaceutical Ingredient Market: By Country
7.9 United States Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
7.10 United States Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
7.11 Canada Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
7.12 Canada Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8. Europe Active Pharmaceutical Ingredient Market: An Analysis (2016-2026)
8.1 Europe Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.2 Europe Active Pharmaceutical Ingredient Market - Prominent Companies
8.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others)
8.4 Market Segmentation By Drug Type (Generic API and Innovative API)
8.5 Market Segmentation By Synthesis (Synthetic and Biotech)
8.6 Europe Active Pharmaceutical Ingredient Market: Country Analysis
8.7 Market Opportunity Chart of Europe Active Pharmaceutical Ingredient Market - By Country, By Value, 2026
8.8 Competitive Scenario of Europe Active Pharmaceutical Ingredient Market: By Country
8.9 Germany Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.10 Germany Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8.11 United Kingdom Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.12 United Kingdom Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8.13 France Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.14 France Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8.15 Spain Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.16 Spain Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8.17 Italy Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.18 Italy Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
9. Asia Pacific Active Pharmaceutical Ingredient Market: An Analysis (2016-2026)
9.1 Asia Pacific Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Active Pharmaceutical Ingredient Market - Prominent Companies
9.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others)
9.4 Market Segmentation By Drug Type (Generic API and Innovative API)
9.5 Market Segmentation By Synthesis (Synthetic and Biotech)
9.6 Asia Pacific Active Pharmaceutical Ingredient Market: Country Analysis
9.7 Market Opportunity Chart of Asia Pacific Active Pharmaceutical Ingredient Market - By Country, By Value, 2026
9.8 Competitive Scenario of Asia Pacific Active Pharmaceutical Ingredient Market: By Country
9.9 China Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
9.10 China Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
9.11 Japan Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
9.12 Japan Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
9.13 India Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
9.14 India Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
10. Global Active Pharmaceutical Ingredient Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Application, 2026
11.2 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Drug Type, 2026
11.3 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Synthesis, 2026
11.4 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Region, 2026
12. Competitive Landscape
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
12.2 Market Share Analysis
13. Company Analysis
13.1 Pfizer Inc.,
13.2 GlaxoSmithKline
13.3 AbbVie Inc.
13.4 Novartis AG
13.5 Eli Lilly and Company
13.6 Merck KGaA
13.7 Teva Pharmaceutical Industries Ltd.
13.8 Sanofi
13.9 Bristol-Myers Squibb
13.10 Boehringer Ingelheim
Request Sample 
Request Discount 
Inquire Before Buy
